Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical

Stock News

02/02

Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. ("Jichuan Limited"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. ("Puqi Pharmaceutical").

The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.

Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).

According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.

Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1192368771"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192368771\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192368771?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192368771","market":"fut","top_or_hot":-1,"title":"Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical","media":"Stock News","content":"<p>Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").</p>\n<p>The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.</p>\n<p>Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).</p>\n<p>According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.</p>\n<p>Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHubei Jumpcan Pharmaceutical (600566.SZ) Subsidiary Signs Exclusive Commercialization Agreement with Puqi Pharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-02 18:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").</p>\n<p>The agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.</p>\n<p>Jichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).</p>\n<p>According to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.</p>\n<p>Upon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1192368771","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192368771","pubTimestamp":1770028508,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600566":"济川药业","BK0028":"国家队","BK0239":"医药制造","09939":"开拓药业-B","BK0201":"可转债","BK0188":"融资融券","BK1515":"抗疫概念","BK1161":"生物科技","BK0012":"证金概念","BK0077":"质押式回购","BK1574":"生物医药B类股","BK0187":"一线龙头"},"translate_title":"湖北跃普康制药（600566.SZ）子公司与普祺制药签署独家商业化协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600566":1,"09939":1},"content_text":"Hubei Jumpcan Pharmaceutical Co.,Ltd. (600566.SZ) announced that its wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd. (\"Jichuan Limited\"), has entered into an exclusive commercialization agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (\"Puqi Pharmaceutical\").\nThe agreement grants Jichuan Limited exclusive rights to commercialize Puqi Pharmaceutical's Pumeixitinib (PG-011) nasal spray in China for the duration of the collaboration.\nJichuan Limited will pay Puqi Pharmaceutical an exclusive commercialization rights fee of up to a maximum of RMB 100 million (including tax).\nAccording to the announcement, Pumeixitinib (PG-011) is a JAK1/2 inhibitor with independent intellectual property rights, developed for the treatment of allergic rhinitis.\nUpon completion of the transaction, the company will further enhance the diversity of its product pipeline, which is conducive to the sustainable development of its business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}